The $TRILLION Opportunity in CRISPR & DNA Sequencing Technologies

July 16, 2018 admin Healthcare, Investing Strategy Comments Off on The $TRILLION Opportunity in CRISPR & DNA Sequencing Technologies

Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.




Related Articles

CEO Interview

Clean Coal Technologies (OTC: CCTC) “Game Changer” technology for the $50 billion coal market?

January 21, 2018 admin CEO Interview, Industrials, Spotlight Stocks Comments Off on Clean Coal Technologies (OTC: CCTC) “Game Changer” technology for the $50 billion coal market?

  Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]

CEO Interview

CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019

January 3, 2019 admin CEO Interview, Healthcare, Spotlight Stocks Comments Off on CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019

  Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]

Healthcare

CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

July 1, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

CytoDyn Signs Non-binding Agreement for Diagnostic Licenseand Supply Agreement with IncellDX for PA-14 and/or PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of […]